Scapa TPP for Remedy

scapa-technologies-tpp

Scapa Test and Performance Platform (TPP) Products

For your end-users, customers and for your business, the performance, scalability, capacity, continuity and reliability of your mission-critical IT systems and their delivery methods must be assured otherwise there will be a significant impact on return on investment (ROI) as well as morale, service delivery and ultimately, the bottom line.

It is not uncommon, however, for performance issues to delay IT deployments. A system may perform well when the number of concurrent users is small, but drastic deterioration can occur with just a modest increase in the number of users, despite compensating hardware enhancements. To ensure continued success, businesses need a solution to minimize, if not eliminate these risks.

Scapa TPP is an innovative and powerful benchmarking, performance testing, diagnosis and monitoring software product. Because Scapa TPP is an independent tool, it is applicable to a wide-range of commercial software technologies, across multiple points in the lifecycle. This includes:

  • BMC Software® Remedy® AR System® product set – including ITSM® suite
  • Citrix® XenApp™
  • Citrix® XenDesktop™
  • Microsoft® Remote Desktop Services®
  • VMware® View™
  • Web Applications
  • ODBC

All of the functionality is available in a single product and can be applied in combination, allowing Scapa TPP to:

  • Perform all types of testing across the project lifecycle.
  • Function in virtual architectures of any complexity.
  • Facilitate migration projects between physical or virtual architectures in any combination and of any complexity.
  • Assist your business decision-making process by allowing you to compare technologies before committing your IT budget.

To learn more about software performance testing, please click here.

To learn how Scapa Test and Performance Platform can leverage your BMC Software investment, you can contact a Column office, have Column contact you, or chat with a Column representative.